HAP Trading’s IGM Biosciences IGMS Stock Holding History

HAP Trading’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-22,814	Closed	-$610K	–	2143
2022 Q1	$610K	Buy	+22,814	New	+$425K	0.03%	476

Other funds holding IGMS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HAP Trading's IGMS Position: Q2 2022 in Review

HAP Trading sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 22,814 shares — an estimated $610K sold.

HAP Trading first reported a position in IGMS in Q1 2022 and held it in 1 quarter. The position peaked at $610K in Q1 2022. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

HAP Trading reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
HAP Trading sold 22,814 IGM Biosciences shares in Q2 2022, an estimated $610K.
HAP Trading first reported a position in IGM Biosciences in Q1 2022 and held it in 1 quarter.
HAP Trading's IGM Biosciences position peaked at $610K in Q1 2022.
89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on HAP Trading's 13F filing for Q2 2022, filed 12 Aug 2022.